首页> 外文期刊>The Journal of Urology >Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy.
【24h】

Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy.

机译:评价当代接受根治性膀胱切除术的患者中淋巴结密度的相关性。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: Lymph node density, that is the ratio of positive nodes to the total number of nodes excised, has been suggested to better stratify patients with bladder cancer who have nodal metastasis. We evaluated its relevance in a contemporary series of patients treated with radical cystectomy and in the context of adjuvant chemotherapy. MATERIALS AND METHODS: From 1993 to 2003, 150 patients had pN+M0 disease at cystectomy, of whom 108 who did not receive neoadjuvant chemotherapy form the basis of this report. Statistical analyses were performed using standard methodology. RESULTS: Five-year overall, disease specific and recurrence-free survival rates were 30.9%, 45.5% and 29.7%, respectively. The median number of lymph nodes removed was 12 and the median number of positive nodes was 2. Of the patients 70% received adjuvant chemotherapy. Patients with a lymph node density of 25% or less had 5-year overall and recurrence-free survival rates of 37.3% and 38.1% compared with 18.7% and 10.6%, respectively inthose with a lymph node density of greater than 25% (p = 0.02). In the context of adjuvant chemotherapy, which was associated with prolonged overall, disease specific and recurrence-free survival (p < or =0.01), lymph node density still remained prognostic for recurrence-free survival (HR 1.69, p = 0.047). The total number of nodes removed and the number of positive nodes were not prognostic. CONCLUSIONS: Our results support the relevance of lymph node density in a contemporary series of patients with bladder cancer treated with radical cystectomy. Lymph node density remains a significant prognostic factor for recurrence-free survival even when adjuvant chemotherapy is used.
机译:目的:淋巴结密度,即阳性淋巴结与切除的淋巴结总数之比,​​已被建议更好地将淋巴结转移的膀胱癌患者分层。我们评估了其在当代行根治性膀胱切除术和辅助化疗的患者中的相关性。材料与方法:从1993年到2003年,有150例膀胱切除术患者患有pN + M0疾病,其中108例未接受新辅助化疗的患者成为本报告的基础。使用标准方法进行统计分析。结果:五年总体,疾病特异性生存率和无复发生存率分别为30.9%,45.5%和29.7%。去除淋巴结的中位数为12,阳性淋巴结的中位数为2。在这些患者中,有70%接受了辅助化疗。淋巴结密度小于或等于25%的患者的5年总生存率和无复发生存率分别为37.3%和38.1%,而淋巴结密度大于25%的患者分别为18.7%和10.6%(p = 0.02)。在辅助化疗与总体,疾病特异性和无复发生存期延长相关(p <或= 0.01)的情况下,淋巴结密度仍为无复发生存期的预后(HR 1.69,p = 0.047)。切除的结节总数和阳性结节数不能预后。结论:我们的研究结果支持了行根治性膀胱切除术治疗的一系列当代膀胱癌患者中淋巴结密度的相关性。即使使用辅助化疗,淋巴结密度仍是无复发生存的重要预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号